TY - JOUR
T1 - Clinical Outcomes After Heterogeneous Overlap Stenting With Drug-Eluting Stents and Bare-Metal Stents for de Novo Coronary Artery Narrowings
AU - Aoki, Jiro
AU - Kirtane, Ajay J.
AU - Dangas, George D.
AU - Lansky, Alexandra J.
AU - Morales, Andy
AU - Kimura, Masashi
AU - Kim, Young Hak
AU - Moussa, Issam
AU - Weisz, Giora
AU - Kreps, Edward M.
AU - Collins, Michael
AU - Frankin-Bond, Theresa
AU - Stone, Gregg W.
AU - Moses, Jeffrey W.
AU - Leon, Martin B.
AU - Mehran, Roxana
PY - 2008/1/1
Y1 - 2008/1/1
N2 - When it is difficult to deliver multiple drug-eluting stents (DES) or when size constraints limit DES implantation, bare-metal stents (BMS) may be implanted contiguous to DES. However, the clinical outcomes after overlapping DES and BMS implantation are not known. From September 2004 to June 2006, 4,872 consecutive patients who underwent percutaneous coronary intervention consented to be enrolled in a prospective registry. Of these patients, 44 (0.9%) with de novo lesions were treated with DES and BMS overlap stenting. All patients were followed to 12 months for the assessment of clinical outcomes. The average implanted stent diameter was 2.68 ± 0.30 mm for DES and 2.35 ± 0.38 mm for BMS. Overlapping BMS were implanted distal to DES in all but 1 case. One patient (2.3%) experienced acute stent thrombosis and died 2 days after the procedure. No other patient died or had a myocardial infarction during 12 months. The target vessel revascularization rate at 12 months, however, was 31.8%, mainly driven by diffuse in-stent restenosis in the BMS segments. In conclusion, the incidence of DES and BMS overlap stenting is rare in daily practice, but this procedure is associated with a high rate of target vessel revascularization.
AB - When it is difficult to deliver multiple drug-eluting stents (DES) or when size constraints limit DES implantation, bare-metal stents (BMS) may be implanted contiguous to DES. However, the clinical outcomes after overlapping DES and BMS implantation are not known. From September 2004 to June 2006, 4,872 consecutive patients who underwent percutaneous coronary intervention consented to be enrolled in a prospective registry. Of these patients, 44 (0.9%) with de novo lesions were treated with DES and BMS overlap stenting. All patients were followed to 12 months for the assessment of clinical outcomes. The average implanted stent diameter was 2.68 ± 0.30 mm for DES and 2.35 ± 0.38 mm for BMS. Overlapping BMS were implanted distal to DES in all but 1 case. One patient (2.3%) experienced acute stent thrombosis and died 2 days after the procedure. No other patient died or had a myocardial infarction during 12 months. The target vessel revascularization rate at 12 months, however, was 31.8%, mainly driven by diffuse in-stent restenosis in the BMS segments. In conclusion, the incidence of DES and BMS overlap stenting is rare in daily practice, but this procedure is associated with a high rate of target vessel revascularization.
UR - http://www.scopus.com/inward/record.url?scp=37349118350&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37349118350&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2007.07.049
DO - 10.1016/j.amjcard.2007.07.049
M3 - Article
C2 - 18157966
AN - SCOPUS:37349118350
SN - 0002-9149
VL - 101
SP - 58
EP - 62
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 1
ER -